Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer

Anticancer Research

Volumn 19, Issue 1 B, 1999, Pages 799-803

  Wagner, Wolfgang ^a   Alfrink, Martin ^a   Haus, Ulrike ^b   Matt, Joachim ^b  

^a Paracelsus Klinik Osnabruck   (Germany)

^b Novartis Pharma GmbH   (Germany)

Author keywords

Head and neck cancer; Irradiation induced mucositis; rhGM CSF

Indexed keywords

ALKALINE PHOSPHATASE; CYTOKINE; GROWTH FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE PAIN; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEVER; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; MACROPHAGE; MUCOSA INFLAMMATION; PAIN; PRIORITY JOURNAL; RADIATION DOSE; SCORING SYSTEM; SUBCUTANEOUS DRUG ADMINISTRATION;

GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; MOUTH MUCOSA; PILOT PROJECTS; RADIOTHERAPY; RECOMBINANT PROTEINS; STOMATITIS; TREATMENT OUTCOME;

EID: 0032898316     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Verdi CJ: Cancer therapy and oral mucositis. An appraisal of drug prophylaxis. Drug Saf 9: 185-195, 1993.
2. Franzen L, Funegard U, Ericson T and Henrikson R: Parotid gland function during and following radiotherapy of malignancies in the head and neck. A consecutive study of salivary flow and patient discomfort. Eur J Cancer 28: 457-462, 1992.
3. Kaplan P: Mantle irradiation of the major salivary glands. J Prosthet Dent 54: 681-686, 1985.
4. Liu RP, Fleming TJ, Toth BB and Keene HJ: Salivary flow rates in patients with head and neck cancer 0.5 to 25 years after radiotherapy. Oral Surg Oral Med Oral Pathol 70: 724-729, 1990.
5. Markitziu A, Zafiropoulos G, Tsalikis L and Cohen L: Gingival health and salivary function in head and neck-irradiated patients. Oral Surg Oral Med Oral Pathol 73: 427-433, 1992.
6. Marks JE: Mucosal protectants and their application for head and neck chemoirradiation. Curr Opin Oncol 9: 267-273, 1997.
7. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan SA, Oette D and Whitley M: Effect of recombinant human granulocyte macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319: 593-598, 1988.
8. Fleischmann J, Golde DW, Weisbart GM and Gasson JC: Granulocyte-macrophage colony-stimulating factor enhances phagocytosis of bacteria by human neutrophils. Blood 68: 7, 1986.
9. Baldwin GC, Gasson JC, Quan SG, Fleischmann J, Weisbart R, Oette D. Mitsuyasu RT and Golde DW: GM-CSF enhances neutrophil function in AIDS patients. Proc Natl Acad Sci USA 85: 2763, 1988.
10. Bleiberg I, Riklis I and Fabian K: Enhanced resistance of bone marrow transplanted mice to bacterial infection induced by recombinant granulocyte-macrophage colony- stimulating factor. Blood 75: 1262, 1990.
11. Mellstedt H, Frîdin JE, Ragnhammer P. Masucci G, Ljungberg A, Hjelm AL, Fagerberg J, Lindemalm C, Osterborg and Wersall P: Therapy of colorectal carcinoma with monoclonal antibodies (MAbl7-IA) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). Acta Oncol 30: 923, 1991.
12. De Vries EGE, Biesma B, Willemse PH, Mulder NH, Stern AC, Aalders JG and Vellenga E: A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 51: 116-122, 1991.
13. Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, Gerhartz D, Hartlapp JH, Thiel E, Huber C, Peschl C, Spann W, Emmerich B, Schadek C, Westerhausen M, Pees HW, Radtke H, Engert A, Terhardt E, Schick H, Binder T, Fuchs R, Hasford J, Brandmaier R, Stern AC, Jones TC, Ehrlich HJ, Stein H, Parwaresch M, Tiemann M and Lennert K: Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant Non-Hodgkin lymphomas. Blood 82: 2329-2339, 1993.
14. Ausili-Cefaro G, Marmiroli L, Fincato G, Nardone L, Scapati AM, Andrulli AD, Genovesi D and Salvi G: Comparison between rhGM-CSF and rhG-CSF administered during radiotherapy and after prolonged carboplatin infusion in preventing leucopenia and mucositis produced by chemoradiothcrapy in advanced head and neck cancer. Eur J Cancer 31 (Suppl. 5): 56, 1995.
15. Ho AD, Del Valle F, Haas R, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Thiel E, Andreesen R, Fiedler W, Frisch J, Schulz G and Hustein W: Sequential studies on the role of mitoxantrone, high-dose cytarabine and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-hodgkin's lymphoma. Sem Oncol 17: 14-19, 1990.
16. Kannan V, Bapsy PP, Anantha N, Doval DC, Vaithianathan H, Banumathy G, Reddy KB, Kumaraswamy SV and Shenoy AM: Efficacy and safety of granulocyte-macrophage colony-stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma. Int J Radiat Oncol Biol Phys 37: 1005-1010, 1997.
17. Eilers J, Berger AM and Petersen MC: Development, testing and application of the oral assessment guide. Oncol Nurs Forum Vol. 15 No. 3: 256-330, 1988.
18. Moore DF and Pazdur R: Phase I study of 5-fluorouracil with folinic acid combined with recombinant human granulocyte-macrophage colony-stimulating factor. Am J Clin Oncol 15: 464-466, 1992.
19. Wardley AM and Scarffe JH: Role of granulocyte-macrophage colony-stimulating factor in chemoradiotherapy-induced oral mucositis. J Clin Oncol 14: 1741-1742, 1996.
20. Troussard X, Macro M, Vie B, Batho A, Peny AM, Reman O, Tabah I and Leporrier M: Human recombinant granulocyte-macrophage colony stimulating factor (rhGM-CSF) improves double hemibody irradiation (DHBI) tolerance in patients with stage III multiple myeloma: a pilot study. Br J Haematol 89: 191-195, 1995.
21. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A and Bonadonna G: Granulocyte-macrophage colony-stimulating factor to harvest circulating hemopoietic stemm cells for autotransplantation. Lancet 9: 580-584, 1989.
22. Nemunaitis J, Rosenfeld CS, Ash R, Freedman MH, Deeg HJ, Appelbaum F, Singer JW, Flomenberg N, Dalton W, Elfenbein GJ, Rifkin R, Rubin A, Atosti J, Hayes FA, Holcenberg J and Shadduck RK: Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplantat 15: 949-954, 1995.
23. Gordon B, Spadinger A, Hodges E, Rubi E, Stanley R and Coccia P: Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis after hematopoietic stem-cell transplantation. J Clin Oncol 12: 1917-1922, 1994.
24. Chi KH, Chen CH, Chan WK, Chow KC, Cheng SY, Yen SH, Chao JY, Chang CY and Chen KY: Effect of granulocyte- macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluoruracil, and leucovorin chemotherapy. J Clin Oncol 13: 2620-2628, 1995.
25. Rosso M, Blasi G, Gherlone E and Rosso R: Effect of granulocyte-macrophage colony-stimulating factor on prevention of mucositis in head and neck cancer patients treated with chemo-radiotherapy. J Chemother 5: 382-385, 1997.
26. Cartee L, Petros WP, Rosner GL, Gilbert C, Moore S, Affronti ML, Hoke JA, Hussein AM, Ross M, Rubin P, Vredenburgh JJ and Peters WP: Evaluation of GM-CSF mouthwash for prevention of chemotherapy-induced mucositis: a randomized, double-blind, dose-ranging study. Cytokine 7: 471-477, 1995.
27. Martin MV: Irradiation mucositis: a reappraisal. Eur J Cancer B Oral Oncol 29B: 1-2, 1993.
28. Sonis S, Muska A, O'Brien J, Van Vugt A, Langer-Safer P and Keith J: Alteration in the frequency, severity and duration of chemotherapy-induced mucositis in hamsters by interleukin-11. Eur J Cancer B Oral Oncol 31: 261-266, 1995.
29. Simpson DM and Ross R: The neutrophilic leucocyte in wound repair: a study with antineutrophil serum. J Clin Invest 51: 2009-2023, 1972.